Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 7Thoracic 2Head & Neck 2Sarcoma 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 65Lymphoma 59Lymphoma, Follicular 53Lymphoma, Large B-Cell, Diffuse 51Lymphoma, B-Cell 50Leukemia, Lymphocytic, Chronic, B-Cell 34Lymphoma, Non-Hodgkin 33Recurrence 27Leukemia 22Lymphoma, Mantle-Cell 20Burkitt Lymphoma 18Lymphoma, T-Cell, Peripheral 17Leukemia, Myeloid, Acute 15Hodgkin Disease 15Waldenstrom Macroglobulinemia 14Hematologic Neoplasms 14Lymphoma, B-Cell, Marginal Zone 13Multiple Myeloma 12Lymphoma, T-Cell, Cutaneous 12Lymphoma, Extranodal NK-T-Cell 12Neoplasms 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, B-Cell 8Motor Activity 7Myelodysplastic Syndromes 6Mycosis Fungoides 6Sezary Syndrome 5Neoplasm, Residual 5Lymphoma, T-Cell 5Pain 4

Interventions

Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Clear-cell metastatic renal cell carcinoma × Lymphoid × Clear all
NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Fred Hutchinson Cancer Center

Phase 2 Not yet recruiting
50 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡